Sage: Phase 3 Study Of Zuranolone On Major Depressive Disord

WESTON (dpa-AFX) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that the phase 3 CORAL study in people with major depressive disorder met its primary and key secondary endpoints. The

Related Keywords

Kostenloser Wertpapierhandel , Sage Therapeutics Inc , Biogen Inc , Care Antidepressant , Care Co Initiated , New Drug Application , Sage , Hase , Study , Zuranolone , Major , Depressive , Disorder , Meets , Primary , Secondary , Endpoints ,